"We Know We Will Emerge Stronger In The U.S.," Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Japan's third-largest drug maker, Daiichi Sankyo, acquired a 64- percent stake in India's most internationally known pharmaceutical brand - Ranbaxy - last June. The deal between an emerging innovator and an established generics drug maker surprised many, but was seen as a transformational one with a goal to expand reach and enhance cost efficiencies. Daiichi Sankyo was criticized later as concerns surfaced regarding Ranbaxy's manufacturing standards at two of its U.S.FDA-approved sites in India. After a complete management overhaul that saw Ranbaxy's promoter exiting the company, Daiichi Sankyo made Atul Sobti the CEO and managing director. In arguably the most in-depth interview after taking over the reins of Ranbaxy, Sobti, who has worked previously with companies like Hero Honda, opened up to PharmAsia News' India bureau on issues spanning U.S. FDA's actions to rebuilding Ranbaxy's reputation and opportunities in Europe, Africa, Japan and India.
You may also be interested in...
Ranbaxy Shuffles Its CEO Again, Atul Sobti Steps Down As Daiichi Sankyo Appoints New Leader
MUMBAI - In a span of less than 15 months, Ranbaxy - now part of Japanese pharma Daiichi Sankyo - will see a second changing of the guard, as chief executive Atul Sobti steps down and hands over the reigns to Arun Sawhney, presently serving as president of Ranbaxy's global pharmaceutical business. Sawhney's promotion to managing director is effective Aug. 20
Ranbaxy Shuffles Its CEO Again, Atul Sobti Steps Down As Daiichi Sankyo Appoints New Leader
MUMBAI - In a span of less than 15 months, Ranbaxy - now part of Japanese pharma Daiichi Sankyo - will see a second changing of the guard, as chief executive Atul Sobti steps down and hands over the reigns to Arun Sawhney, presently serving as president of Ranbaxy's global pharmaceutical business. Sawhney's promotion to managing director is effective Aug. 20
CEO Shuffle: Daiichi Sankyo Appoints Second New Ranbaxy Leader In Less Than 15 Months
The Indian drug maker will see a changing of the guard, as chief executive Atul Sobti steps down and hands over the reins to Arun Sawhney, presently serving as president of Ranbaxy's global pharmaceutical business.